Antiangiogenic therapies in glioblastoma multiforme

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

(2011) O. L. Chinot et al.   ADVANCES IN THERAPY

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

(2011) N. Butowski et al.   NEURO-ONCOLOGY

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

(2011) P. Y. Wen et al.   NEURO-ONCOLOGY

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study

(2011) E. Hattingen et al.   NEURO-ONCOLOGY

Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome

(2011) T. J. Lehky et al.   NEUROLOGY

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma

(2010) Louis B. Nabors et al.   ARCHIVES OF NEUROLOGY

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

(2010) John D. Hainsworth et al.   CANCER

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Bevacizumab

(2010) Marit D. Moen   DRUGS

Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model

(2010) Wibom   INTERNATIONAL JOURNAL OF ONCOLOGY

Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma

(2010) Jan Drappatz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure

(2010) C. Lu-Emerson et al.   JOURNAL OF NEURO-ONCOLOGY

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

(2010) Elizabeth R. Gerstner et al.   JOURNAL OF NEURO-ONCOLOGY

Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2

(2010) Roni Mamluk et al.   mAbs

Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3

(2010) Fan Yang et al.   MOLECULAR CANCER THERAPEUTICS

The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases

(2010) R. S. Bhide et al.   MOLECULAR CANCER THERAPEUTICS

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

(2010) M. R. Gilbert et al.   NEURO-ONCOLOGY

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

(2010) F. M. Iwamoto et al.   NEURO-ONCOLOGY

Sorafenib exerts anti-glioma activity in vitro and in vivo

(2010) Markus D. Siegelin et al.   NEUROSCIENCE LETTERS

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

(2009) David A. Reardon et al.   CANCER

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

(2009) L. Xu et al.   CANCER RESEARCH

EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

(2009) Alba A. Brandes et al.   EUROPEAN JOURNAL OF CANCER

Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness

(2009) Ahlame Saidi et al.   INTERNATIONAL JOURNAL OF CANCER

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

(2009) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

(2009) Walid S. Kamoun et al.   JOURNAL OF CLINICAL ONCOLOGY

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

The Hardest Job in Medicine

(2009) Richard C. Frank   JOURNAL OF CLINICAL ONCOLOGY

In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation

(2009) E. Ranza et al.   JOURNAL OF NEURO-ONCOLOGY

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

(2009) Gregor Dresemann et al.   JOURNAL OF NEURO-ONCOLOGY

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

(2009) V. Milano et al.   MOLECULAR CANCER THERAPEUTICS

Adverse effects of anticancer agents that target the VEGF pathway

(2009) Helen X. Chen et al.   Nature Reviews Clinical Oncology

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro

(2009) Gabriele D. Maurer et al.   NEURO-ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

SURROGATE MARKERS PREDICT ANGIOGENIC POTENTIAL AND SURVIVAL IN PATIENTS WITH GLIOBLASTOMA MULTIFORME

(2009) Jeffrey P. Greenfield et al.   NEUROSURGERY

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

(2008) Tom Mikkelsen et al.   INTERNATIONAL JOURNAL OF CANCER

A Pilot Safety Study of Lenalidomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2008) Jan Drappatz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

(2008) Anastasia Murat et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme

(2008) Camilo E. Fadul et al.   JOURNAL OF NEURO-ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

(2008) Jinyan Du et al.   NATURE BIOTECHNOLOGY

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

(2008) Vinay K. Puduvalli et al.   NEURO-ONCOLOGY

VEGF Trap induces antiglioma effect at different stages of disease

(2008) Candelaria Gomez-Manzano et al.   NEURO-ONCOLOGY

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

(2008) Cristiana Sessa et al.   Nature clinical practice. Oncology